No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 65
Sex
Any
Study type
Observational
Participants needed
750 (estimated)
Sponsor
National Institute of Environmental Health Sciences (NIEHS) · NIH
Who this trial is looking for
This trial is looking for healthy adults ages 18 to 65 to help understand how immune cells respond to different signals. Participants will donate some blood, which will be analyzed to learn more about inflammation responses.
Are You a Good Fit for This Trial?
Rules you outAnemiaHeart problemsInsulin dependent diabetesCreutzfeldt-Jacob Disease
You may be able to join if
I am a healthy adult aged 18-65.
I weigh at least 110 pounds.
I am not pregnant.
I am HIV negative.
I am hepatitis B and C negative.
You may not be able to join if
I have felt ill in the last 24 hours.
I have consumed alcohol in the last 24 hours.
I visited the dentist in the last 24 hours.
I had a doctor visit for illness or vaccination in the last 2 weeks.
I have diarrhea in the last 2 weeks.
I have recurrent fever.
I have a bleeding disorder.
I am HIV positive or hepatitis B/C positive.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study will investigate the response of immune cells (neutrophils, monocytes) to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of …
This study will investigate the response of immune cells (neutrophils, monocytes) to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.
Healthy normal volunteers 18 years of age and older who weigh at least 110 pounds may be eligible for this study. Participants give about 320 milliliters (mL) of blood (about 1 1/3 cups) or less at each donation. They donate no more than once every 8 weeks and no more than six times a year. On some occasions, less than 320 mL of blood may be drawn. The collected blood is separated into its components and specific cells are exposed to substances to examine their response.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
* INCLUSION CRITERIA:
* Normal, healthy adult donors as judged by screening questionnaire
* Nonpregnant
* Weighing at least 110 lbs
* 18-65 years of age
* HIV negative (proof required every 6 months we will conduct test)\*
* Hepatitis B surface antigen and hepatitis C serology negative (checked ever…
* INCLUSION CRITERIA:
* Normal, healthy adult donors as judged by screening questionnaire
* Nonpregnant
* Weighing at least 110 lbs
* 18-65 years of age
* HIV negative (proof required every 6 months we will conduct test)\*
* Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)\*
* The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow
All positive HIV, hepatitis B, and hepatitis C results will be promptly communicated to the donor by the study doctor/PI or the CRU Director. The participant will be referred to their physician and/or to the N.C. Department of Health for confirmatory testing and counseling. As explained in detail in the attached Supplement describing N.C. State Department of Health code will be followed. The state code mandates reporting of positive results along with the participant s name and identifying information to the N.C. Department of Public Health. Upon contracting with the testing laboratory, clarification will be obtained and documented as to whether the contracted laboratory or the study MD will be responsible for reporting positive results to the state to avoid duplication of reporting. Upon receipt of the test results, the N.C. Department of Health will contact the participant to inform them of the positive result, how to find care, how to avoid infecting others, how the newly diagnosed HIV and/or hepatitis infection is reported, and the importance of informing their partners at possible risk because of their HIV and/or hepatitis infection. If the HIV, hepatitis B, and hepatitis C results are negative, the participant will be not be notified. However, the participant may contact the research study nurse for their results.
HIV and hepatitis B/C test results, non-reactive and reactive, will be documented confidentially by the PI or study coordinator in the subject s file, and kept in a locked file cabinet in the CRU Medical Records Room.In order to document the reporting procedure and the time associated with the reporting process, a document has been created and placed in the study specific manual (Hepatitis B/C and HIV Notification Process for Reactive Results Form)
EXCLUSION CRITERIA:
By questionnaire:
Feeling ill within the last 24 hours.
Alcohol consumption in the last 24 hours.
Visit to the dentist in the last 24 hours.
A doctor visit for illness or vaccination in the last 2 weeks.
Diarrhea in the last 2 weeks.
Recurrent fever (4 weeks).
Pregnant or suspected pregnancy in the last 6 weeks.
Blood or plasma donation that will cause the participant to exceed 550ml of blood in the last 8 weeks.
Receiving a blood donation in the past 12 months.
Bleeding disorder.
Anemia.
Heart problems.
Insulin dependent diabetes.
Problems with blood donation.
Risk of or evidence of Creutzfeldt-Jacob Disease in the family.
HIV-positive status, Hepatitis B/C-positive status or other confirmed or suspected immunosuppressive or immunodeficient conditions.
Use of immunosuppressants or other immune-modifying drugs.
Use of selected medications within the preceding 5 days unless the PI or AI receiving the samples states otherwise (NSAIDS/aspirin/tylenol, antidepressants, antihistamines , corticosteroids, HMG CoA reductase inhibitors, and antihypertensives).
By exam:
Temperature over 99.5 F.
Blood pressure less than 90/50.
Blood pressure higher than 170/95 mm Hg.
Pulse rate less than 50 or greater than 100 beats/minute.
If blood donation exceeds 200ml:
* Hematocrit less than 34% for women or less than 36% for men, or greater than 56% for either gender.
* Patients will be informed of disqualifying vital signs and hematocrit values and advised by trained staff, as appropriate, to seek assistance from their physician.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.